Results 101 to 110 of about 120,218 (287)

Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma [PDF]

, 2018
Muhammad Zubair Afzal, Rima R. Mercado, Keisuke Shirai   +2 more
openalex   +1 more source

CD16+ Macrophages: An Emerging Biomarker for Combined CTLA-4 and PD-1 Blockade [PDF]

, 2023
James W. Smithy, Jason J. Luke
openalex   +1 more source

Targeting the Mapk13‐Tcf1‐Slc7a5 Axis via One‐Carbon Metabolic Regulation to Prevent Chronic Allograft Vasculopathy

Advanced Science, EarlyView.
This study emphasizes the role of the Mapk13‐Tcf1‐Slc7a5‐methionine metabolism axis in stem‐like CD4+ T cells. Moreover, it uncovers the mechanism through which limiting one‐carbon metabolism in CD4+ stem‐like T cells suppresses the tide of chronic allograft vasculopathy, offering potential targets to promote long‐term graft survival.
Wang Yi, Di Wu, Jing Liu, Shi Chen, Liu Song, Bin Xie, Aini Xie, Peixiang Lan, Zhishui Chen   +8 more
wiley   +1 more source

Lost in Translation: Deciphering the Mechanism of Action of Anti-human CTLA-4 [PDF]

, 2018
Sergio A. Quezada, Karl S. Peggs
openalex   +1 more source

Synergistic Activation of Immunogenic Cell Death and the cGAS–STING Pathway by Engineered Zinc/Manganese‐Based Metal–Organic Framework Nanoplatforms for Colon Cancer Immunotherapy

Advanced Science, EarlyView.
A zinc/manganese (Zn/Mn)‐based metal‐organic framework (MOF) loaded with the STING agonist c‐di‐AMP diammonium (denoted AMP@Zn/Mn‐MOF) was developed to synergistically activate the cGAS‐STING pathway and induce immunogenic cell death. This nanoplatform reprograms the immunosuppressive tumor microenvironment, significantly enhancing anti‐PD‐L1 ...
Bingzi Zhu, Xiaodong Chen, Chang Xu, Xuehua Qian, Binglong Bai, Ji Lin, Wenhai Deng, Xiang Wang, Yuekai Cui, Shengsheng Zhao, Zuoliang Xie, Tao You, Yingpeng Huang, Xian Shen, Xufeng Lu, Weijian Sun   +15 more
wiley   +1 more source

CD25+CD4+ regulatory T cells exert in vitro suppressive activity independent of CTLA-4 [PDF]

, 2005
Hiroshi Kataoka
openalex   +1 more source

Engineered CAR‐NKT Extracellular Vesicles Suppress Tumor Progression and Enhance Antitumor Immunity

Advanced Science, EarlyView.
TM4SF1‐nanobody engineered CAR‐natural killer T–derived extracellular vesicles (CARTM4SF1‐EVs) provide a cell‐free alternative to CAR‐NKT therapy, achieving potent, targeted antitumor activity with reduced toxicity. CARTM4SF1‐EVs induce immunogenic cell death, remodel the tumor microenvironment, and enhance CD8⁺ T‐cell antitumor immunity.
Xiaopei Hao, Chengming Qu, Yanzhao Zhou, Xiaoqian Wang, Xiangjun Qian, Xun Chen, Feng Han, Xiaokai Zhang, Yiyi Ji, Han Li, ChengWei Ju, Peng Xia, Weiwei Tang, Hao Zhuang, Jinxue Zhou   +14 more
wiley   +1 more source

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

Advanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo, Lanjie Lei, Ying Jin, Lan Su, Shumao Cui, Liyun Shi   +5 more
wiley   +1 more source

Supplementary Figure 1 from A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

, 2023
Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J. Haley, Anna Maria Storniolo, Mridula P. Reddy, Scott A. Anderson, Collin T. Zimmerman, Anne O’Dea, Hamid Mirshahidi, Jordi Rodón, FRANK BRESCIA, Olwen Hahn, Jane M. Raymond, David D. Biggs, Roisín M. Connolly, Elad Sharon, Larissa A. Korde, Robert J. Gray, Edward Mayerson, Melissa Plets, Charles D. Blanke, Young Kwang Chae, Razelle Kurzrock   +27 more
openalex   +1 more source

Dual blockade of IL-6 and CTLA-4 regresses pancreatic tumors in a CD4+ T-cell-dependent manner. [PDF]

, 2021
Michael B. Ware, Christopher McQuinn, Mohommad Zaidi, Hannah M. Knochelmann, Brian Robinson, Cameron J. Herting, Thomas A. Mace, Zhengjia Chen, Chao Zhang, Matthew R. Farren, Amanda N. Ruggieri, Jacob S. Bowers, Reena Shakya, Alton B. Farris, Greg Young, William E. Carson, Bassel F. El‐Rayes, Chrystal M. Paulos, Gregory B. Lesinski   +18 more
openalex   +1 more source